Peripheral arterial Disease LDL-C and cardiovascular Risk significantly lowering with Evolocumab

被引：0
作者：
Unger-Hunt, Lydia
机构：
来源：
AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM | 2018年 / 11卷 / 02期
关键词：
D O I：
10.1007/s41969-018-0028-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：68 / 70
页数：3
相关论文
共 50 条
[21]   Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl [J].
Robinson, Jennifer G. ;
Jayanna, Manju Bengaluru ;
Bairey Merz, C. Noel ;
Stone, Neil J. .
PLOS ONE, 2020, 15 (10)
[22]   CONSISTENCY OF LDL-C REDUCTION WITH EVOLOCUMAB: AN ANALYSIS FROM FOURIER [J].
Qamar, Arman ;
Giugliano, Robert P. ;
Keech, Anthony C. ;
Kuder, Julia F. ;
Murphy, Sabina A. ;
Liu, Thomas ;
Kurtz, Christopher ;
Wasserman, Scott M. ;
Sever, Peter S. ;
Pedersen, Terje R. ;
Sabatine, Marc S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) :1727-1727
[23]   Long-Term Neurocognitive Safety of LDL-C Lowering With Evolocumab: OpenLabel Extension Data From FOURIER [J].
Zimerman, Andre ;
O'Donoghue, Michelle ;
Ran, Xinhui ;
Im, KyungAh ;
Ott, Brian F. ;
Mach, Francois ;
Zavitz, Kenton ;
Kurtz, Christopher E. ;
Monsalvo, Maria L. ;
Wang, Bei ;
Atar, Dan ;
Keech, Anthony ;
Sabatine, Marc S. ;
Giugliano, Robert .
CIRCULATION, 2023, 148
[24]   Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China [J].
Yuansheng Wan ;
Jinyu Liu ;
Xiaolian Zhan ;
Yu Zhang ;
Ruxu You .
Cost Effectiveness and Resource Allocation, 21
[25]   Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China [J].
Wan, Yuansheng ;
Liu, Jinyu ;
Zhan, Xiaolian ;
Zhang, Yu ;
You, Ruxu .
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
[26]   BUDGET IMPACT ANALYSIS OF ADOPTING EVOLOCUMAB IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM FOR PATIENTS WITH UNCONTROLLED LDL-C AND HIGH CARDIOVASCULAR RISK [J].
dos Santos, R. E. ;
Alves, F. P. ;
Urbich, M. ;
Villa, G. ;
Farsky, P. S. .
VALUE IN HEALTH, 2017, 20 (09) :A914-A915
[27]   ACHIEVEMENT OF LDL-C TARGETS IN CHINESE PATIENTS WITH VERY HIGH RISK ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RECEIVING INTENSIVE LIPID LOWERING THERAPY [J].
Cheng, Y. ;
Dong, S. ;
Shen, P. ;
Sun, Y. ;
Lin, H. ;
Zhai, S. .
VALUE IN HEALTH, 2022, 25 (01) :S24-S24
[28]   IMPACT OF EVOLOCUMAB THERAPY IN PATIENTS WITH DISCORDANCE BETWEEN LDL-C AND LDL-P [J].
Toth, Peter P. ;
Sattar, Naveed ;
Blom, Dirk ;
Martin, Seth ;
Jones, Steven ;
Monsalvo, Maria Laura ;
Elliott, Mary ;
Somaratne, Ransi ;
Preiss, David .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) :1718-1718
[29]   Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering A Systematic Review and Meta-analysis [J].
Navarese, Eliano P. ;
Robinson, Jennifer G. ;
Kowalewski, Mariusz ;
Kolodziejczak, Michalina ;
Andreotti, Felicita ;
Bliden, Kevin ;
Tantry, Udaya ;
Kubica, Jacek ;
Raggi, Paolo ;
Gurbel, Paul A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (15) :1566-1579
[30]   最新试验证实Evolocumab降LDL-C疗效 [J].
临床合理用药杂志, 2014, (17) :87-87
12345